Improving Diagnostic and Treatment Outcomes for Cholestatic Liver Diseases and Pruritus
Course Overview
Cholestatic liver disease causes liver damage and fibrosis owing to bile stasis. It is represented by primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The pathogenesis of the disease is still unclear, although autoimmune mechanisms have been postulated and partially elucidated. Although the disease may progress slowly with only mild liver dysfunction, it may advance to liver cirrhosis or liver failure. People living with PBC are frequently symptomatic, experiencing a quality-of-life burden dominated by fatigue, itch, abdominal pain, and sicca complex.
As a medical treatment, ursodeoxycholic acid is widely used for PBC and has proved to be very effective against disease progression in cases of PBC. But new treatments are now available or in late-stage development, offering options in addition to Urso.
The seminar will explore the general natural history of PBC and PSC and provide information on the latest drug therapies currently available as well as those under investigation. A special section will focus on the frequent complaint of itching and will focus on the management of Cholestatic Pruritus.
Topics to be addressed in this seminar include:
Discovery and natural history of the Primary Biliary Cholangitis, including the disease’s name change
Rate of Disease progression and why there is such variation
Prevalence and growth PBC in women and in men
The three prominent forms of PBC: How are they alike and how do they differ
The risk of liver failure and death increases as PBC progresses
Managing Pruritis in your PBC patients
Therapeutic agents available in the US for those with PBC and promising clinical trials
The new and emerging therapies for Primary Biliary Cholangitis – Methods of action and potential benefits
PSC diagnosis, natural history, clinical course
PSC treatment with UDCA and other treatments in development
What are the major differences between PBC and PSC
Take-home lessons and Proactive next steps
Available in two formats
A live, face-to-face seminar and a web-based, self-paced activity
All activities are accredited for AMA PRA Category 1 Credit(s)TM
Dates and Locations TBD
Credit Designation
• The Colorado Medical Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this live activity for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.
AANP accepts Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.
AANP accepts Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.
For more information, please contact SCLRC at shoe.aubrey@scliver.com or at cme@scliver.com.
This seminar series is administered by and Continuing Medical Education provided by:
Colorado Medical Society
Office of Continuing Medical Education
7351 Lowry Blvd, Suite 110
Denver, CO 80230
Phone - 720.739.8138
Email:cme@cms.edu
